Display options
Cite
Murrell DF, Arora G, Rudnicka L, et al. A dermatologist's perspective of the COVID-19 outbreak. Dermatol Ther. 2020;33(4):e13538doi: 10.1111/dth.13538.
Murrell, D. F., Arora, G., Rudnicka, L., Kassir, M., Lotti, T., & Goldust, M. (2020). A dermatologist's perspective of the COVID-19 outbreak. Dermatologic therapy, 33(4), e13538. https://doi.org/10.1111/dth.13538
Murrell, Dedee F, et al. "A dermatologist's perspective of the COVID-19 outbreak." Dermatologic therapy vol. 33,4 (2020): e13538. doi: https://doi.org/10.1111/dth.13538
Murrell DF, Arora G, Rudnicka L, Kassir M, Lotti T, Goldust M. A dermatologist's perspective of the COVID-19 outbreak. Dermatol Ther. 2020 Jul;33(4):e13538. doi: 10.1111/dth.13538. Epub 2020 Jun 23. PMID: 32385938; PMCID: PMC7272968.
Copy Download .nbib Format: NLM
Share it on

Dermatol Ther. 2020 Jul;33(4):e13538. doi: 10.1111/dth.13538. Epub 2020 Jun 23.

A dermatologist's perspective of the COVID-19 outbreak.

Dermatologic therapy

Dedee F Murrell, Gulhima Arora, Lidia Rudnicka, Martin Kassir, Torello Lotti, Mohamad Goldust

Affiliations

  1. Department of Dermatology, St George Hospital, Faculty of Medicine, University of New South Wales, Sydney, Australia.
  2. Department of Dermatology, Mehektagul Dermaclinic, New Delhi, India.
  3. Department of Dermatology, Medical University of Warsaw, Warsaw, Poland.
  4. Worldwide Laser Institute, Dallas, Texas, USA.
  5. Department of Dermatology, University of Studies Guglielmo Marconi, Rome, Italy.
  6. University of Rome G. Marconi, Rome, Italy.
  7. Department of Dermatology, University Hospital Basel, Basel, Switzerland.

PMID: 32385938 PMCID: PMC7272968 DOI: 10.1111/dth.13538

[No abstract available.]

References

  1. Sharma A, Fölster-Holst R, Kassir M, et al. The effect of quarantine and isolation for COVID-19 in general population and dermatologic treatments. Dermatol Ther. 2020;10:e13398. https://doi.org/10.1111/dth.13398. - PubMed
  2. Rudnicka L, Gupta M, Kassir M, et al. Priorities for global health community in COVID-19 pandemic. Dermatol Ther. 2020;e13361. Apr 1:e13361. - PubMed
  3. Arora G, Kroumpouzos G, Kassir M, et al. Solidarity and transparency against the COVID-19 pandemic. Dermatol Ther. 2020; Mar 31:edth13359. https://doi.org/10.1111/dth.13359. - PubMed
  4. Recalcati S. Cutaneous manifestations in COVID-19: a first perspective. J Eur Acad Dermatol Venereol. 2020;34(5):e212-e213. http://doi.wiley.com/10.1111/jdv.16387. [Epub ahead of print]. - PubMed
  5. Darlenski R, Tsankov N. Covid-19 pandemic and the skin-what should dermatologists know? Clin Dermatol. 2020;S0738081X20300493. - PubMed
  6. Richmond JM, Harris JE. Immunology and skin in health and disease. Cold Spring Harb Perspect Med. 2014;4:a015339-a015339. - PubMed
  7. Yan Y, Chen H, Chen L, et al. Consensus of Chinese experts on protection of skin and mucous membrane barrier for healthcare workers fighting against coronavirus disease 2019. Dermatol Ther. 2020;e13310. https://onlinelibrary.wiley.com/doi/abs/10.1111/dth.13310. [Epub ahead of print]. - PubMed
  8. Gautret P, Lagier J-C, Parola P, et al. Hydroxychloroquine and azithromycin as a treatment of COVID-19: results of an open-label non-randomized clinical trial. Int J Antimicrob Agents. 2020;105949. - PubMed
  9. Ventricular Arrhythmia Risk Due to Hydroxychloroquine-Azithromycin Treatment for COVID-19-American College of Cardiology [Internet]. American College of Cardiology 2020. https://www.acc.org/latest-in-cardiology/articles/2020/03/27/14/00/ventricular-arrhythmia-risk-due-to-hydroxychloroquine-azithromycin-treatment-for-covid-19. - PubMed

MeSH terms

Publication Types